RecruitingNCT05536388

Drug Discovery for Parkinson's With Mutations in the GBA Gene

Sponsor

New York Stem Cell Foundation Research Institute

Enrollment

60 participants

Start Date

Jul 15, 2022

Study Type

OBSERVATIONAL

Conditions

Healthy Gaucher Disease Parkinson Disease GBA Gene Mutation

Summary

The New York Stem Cell Foundation (NYSCF) Research Institute is performing this research to accelerate Parkinson's disease research and drug development by using cells from the body (such as skin or blood cells) to make stem cells and other types of cells, conduct research on the samples, perform genetic testing, and/or store the samples for future use. Through this research, researchers hope to identify future treatments or even cures for Parkinson's disease.

Eligibility

Min Age: 18 Years

Inclusion Criteria3

Age 18 years or older.
Diagnosis of Parkinson's disease, Gaucher disease, or healthy control.
Must provide written informed consent unless physical limitations preclude signing.

Exclusion Criteria3

For skin samples collected specifically for this study: history of keloid formation, coagulation disorder, allergy to the anesthetic, or anticoagulation use that precludes sample collection.
For blood samples collected specifically for this study: coagulation disorder or other medical condition(s) that increases the risks associated with blood collection.
For all prospective sample collections: Subjects who refuse to adhere to NYSCF's and/or a collection site's safety protocols will be excluded. Subjects with an AIDS diagnosis and CD4 count of less than 200 cells per microliter (mcL) of blood will be excluded due to increased risk of infection.

Interventions

OTHERBiological Sample Collection

Skin biopsy (2-3mm) and/or blood (up to 50 mL); saliva; excess/leftover biospecimens that were (or will be) collected for other purposes (e.g., medical procedure)